Scarica l'app Stockscreener
3.13
4.86%
-0.16
Dopo l'orario di chiusura:
3.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Iovance Biotherapeutics Plummets Amidst Lawsuit and Executive Shake-up - timothysykes.com
Iovance Biotherapeutics Is Waking UpPrice Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Held Back By Insufficient Growth Even After Shares Climb 75% - 富途牛牛
Iovance Biotherapeutics shares rise 5.47% premarket after Pfizer's $1.25 billion licensing agreement for cancer drug. - AInvest
Iovance Biotherapeutics to Host Second Quarter and First - GlobeNewswire
Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling - timothysykes.com
Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World
Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Quiver Quantitative
Here’s why Iova stock surged 32% today and why the rally might not be over - TradingView
Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment - AInvest
Iovance Biotherapeutics’ Remarkable Surge: Time to Dive In? - StocksToTrade
Positive Week for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Institutional Investors Who Lost 64% Over the Past Year - 富途牛牛
Iovance Biotherapeutics’ Unexpected Surge: Is It Time to Buy? - timothysykes.com
Where are the Opportunities in (IOVA) - news.stocktradersdaily.com
What drives Iovance Biotherapeutics Inc. stock priceRapid profit acceleration - jammulinksnews.com
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralyt - Barchart.com
Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha
Iovance Biotherapeutics Shares Soar 14.46% on FDA Approval, Leadership Changes - AInvest
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Evaxion Biotech, Inxmed, Aivita Biomedical, Iovance Biotherapeutics, Viralyt - MenaFN
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Iovance Biotherapeutics Inc Inc. (IOVA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Is Iovance Biotherapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside - The Motley Fool
Teacher Retirement System of Texas Has $191,000 Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Iovance Biotherapeutics Inc. Stock Analysis and ForecastExplosive returns - PrintWeekIndia
Zacks Research Issues Pessimistic Estimate for IOVA Earnings - Defense World
What analysts say about Iovance Biotherapeutics Inc. stockFree Stock Selection - jammulinksnews.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha
Iovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at The Goldman Sachs Group - Defense World
Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid potential - Investing.com
Iovance BioTherapeutics Sees Positive Trends with New Appointments and Promising Cancer Study - StocksToTrade
Iovance Biotherapeutics Appoints New Chief Financial Officer - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Iovance Biotherapeutics: Legal Woes Shake Investor Confidence - timothysykes.com
Iovance Biotherapeutics Faces Legal Hurdles Amid Investor Concerns - StocksToTrade
Iovance Biotherapeutics, Inc. Appoints Corleen Roche as Chief Financial Officer, Effective August 6, 2025 - MarketScreener
Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionMulti Bagger Alerts - Newser
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewswire
Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener
Iovance Biotherapeutics Names Corleen Roche as Chief Financial Officer - MarketScreener
Citizens JMP reiterates Market Perform rating on Iovance stock By Investing.com - Investing.com Canada
Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges - Investing.com Canada
Cambridge Investment Research Advisors Inc. Acquires 5,237 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Amtagvi shows 61% response rate in less heavily treated melanoma patients - Investing.com Australia
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit on July 14, 2025 - openPR.com
Levi & Korsinsky Reminds Iovance Investors of the Pending - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - The Globe and Mail
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):